Journal Home
Search for

Volume 20, Issue 1, Pages 85-89 (January 2009)


View previous. 10 of 12 View next.

Opioid dependent patients’ experiences of and attitudes towards having their injecting sites examined

Adam R. WinstockabCorresponding Author Informationemail address, Maria Nittisa1email address, Gilbert Whittona2email address, Toby Leaa3email address

Received 2 July 2007; accepted 11 November 2007. published online 03 January 2008.

Abstract 

Background

This study explored the attitude towards, and experiences of, injection site examination among injecting drug users in opioid treatment and the potential impact of this routine examination on information disclosure and future injection practices.

Methods

A self-complete, anonymous, cross-sectional questionnaire was used with 153 patients recruited from three public clinics in Sydney, Australia.

Results

The vast majority (97%) had ever injected in their upper limb, 19% in their leg, 16% in their neck, and 7% in their groin. The majority were ‘happy to have their sites inspected’ (78%), and felt it was an ‘appropriate part of routine examination’ (72%). Seventy-seven percent said they would be more honest about recent injecting, and 25% would inject in other sites if upper limb inspection occurred at every clinical review.

Conclusions

The examination of injecting sites can provide useful corroboration of self-reported injecting drug use and an opportunity to offer harm reduction advice. The inspection of injecting sites was acceptable to most patients and should form part of routine clinical reviews.

a Drug Health Services, Sydney South West Area Health Service, Australia

b National Drug and Alcohol Research Centre, University of New South Wales, Australia

Corresponding Author InformationCorresponding author at: Drug Health Services, Locked Bag 4002, Ashfield, NSW 2132, Australia. Tel.: +61 2 9378 1316; fax: +61 2 9378 1338.

1 Tel.: +61 2 4634 4177; fax: +61 2 4634 4190.

2 Tel.: +61 2 9722 8293; fax: +61 2 9722 8959.

3 Tel.: + 61 2 9378 1314; fax: +61 2 9378 1338.

PII: S0955-3959(07)00220-4

doi:10.1016/j.drugpo.2007.11.002


View previous. 10 of 12 View next.